These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28690396)

  • 1. Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
    de Geus SW; Baart VM; Boonstra MC; Kuppen PJ; Prevoo HA; Mazar AP; Bonsing BA; Morreau H; van de Velde CJ; Vahrmeijer AL; Sier CF
    Biomark Insights; 2017; 12():1177271917715443. PubMed ID: 28690396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.
    Boonstra MC; Verbeek FP; Mazar AP; Prevoo HA; Kuppen PJ; van de Velde CJ; Vahrmeijer AL; Sier CF
    BMC Cancer; 2014 Apr; 14():269. PubMed ID: 24742002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients.
    Ahn SB; Chan C; Dent OF; Mohamedali A; Kwun SY; Clarke C; Fletcher J; Chapuis PH; Nice EC; Baker MS
    PLoS One; 2015; 10(2):e0117786. PubMed ID: 25692297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase plasminogen activator receptor on invasive cancer cells: a prognostic factor in distal gastric adenocarcinoma.
    Alpízar-Alpízar W; Christensen IJ; Santoni-Rugiu E; Skarstein A; Ovrebo K; Illemann M; Laerum OD
    Int J Cancer; 2012 Aug; 131(4):E329-36. PubMed ID: 21901747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
    Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
    Cancer; 1998 Feb; 82(4):724-32. PubMed ID: 9477106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
    Cantero D; Friess H; Deflorin J; Zimmermann A; Bründler MA; Riesle E; Korc M; Büchler MW
    Br J Cancer; 1997; 75(3):388-95. PubMed ID: 9020484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
    Yang JL; Seetoo Dq; Wang Y; Ranson M; Berney CR; Ham JM; Russell PJ; Crowe PJ
    Int J Cancer; 2000 Sep; 89(5):431-9. PubMed ID: 11008205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
    Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
    He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
    Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
    Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD
    Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
    Pappot H; Skov BG; Pyke C; Grøndahl-Hansen J
    Lung Cancer; 1997 Jul; 17(2-3):197-209. PubMed ID: 9237155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.